



176

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	<b>10/593,687</b>
	Filing Date	<b>September 19, 2006</b>
	First Named Inventor	<b>Clerc</b>
	Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	<b>22518</b>

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<b>USPTO Form 1449; References</b>	

<b>SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT</b>	
Firm or Individual name	<b>Dennis P. Tramaloni</b>
Signature	
Date	<b>01/16/2007</b>

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	<b>Dennis P. Tramaloni</b>		
Signature		Date	<b>01/16/2007</b>

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

278023

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PATENT APPLICATION



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Patent Application

Inventor(s) Roger G Clerc, et. al.

Group:

Application No. 10/593,687, filed September 19, 2006  
(Case Docket No. 22518)

Examiner:

For: PDK4 AS MARKER FOR PPARDELTA MODULATION

**INFORMATION DISCLOSURE STATEMENT**

Nutley, New Jersey 07110  
January 16, 2007

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents B1 and C1-C11 listed on Form PTO-1449 are enclosed.

Consideration of all the documents cited on Form PTO-1449 is requested.

Appl. No. 10/593,687  
Filed: September 19, 2006

Since the Information Disclosure Statement is submitted before the receipt of the first Office Action on the merits for the above application, it is believed that no fee is due. If a fee is due and owing, please charge to Deposit Account No. 08-2525.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Dennis P. Tramaloni", is written over a horizontal line.

Attorney for Applicant(s)  
Dennis P. Tramaloni  
(Reg. No. 28,542)  
340 Kingsland Street  
Nutley, New Jersey 07110  
Telephone: (973) 235-4475  
Telefax: (973) 235-2363

278021



Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)				<b>Complete if Known</b>	
				Application Number	10/593,687
				Filing Date	September 19, 2006
				First Name Inventor	Clerc
				Group Art Unit	
				Examiner Name	
Sheet	2	Of	2	Attorney Docket Number	22518

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>7</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	C1	Holness, M.J., et. al., Regulation of pyruvate dehydrogenase..., Biochemical Society, V. 31, N. 6 (2003) 1143-1151	
	C2	Huang, Boli, et. al., Regulation of pyruvate dehydrogenase.... Diabetes, V. 51, N. 2 (2/2002) 276-283	
	C3	Dong, J et. al., Faseb Journal, V 15, N. 4 (2001) p. A197	
	C4	Wu, Pengfei et. al., Mechanism responsible for inactivation..., Diabetes, V. 48, N. 8 (1999) p. 1593-1599	
	C5	Minnick, Dana etal. Correlation of change in gene expression..., (2003) Philadelphia	
	C6	Diabetes, V. 52, No 1 supplement p. A127, 63 <sup>rd</sup> scientific sessions New Orleans, LA 6/2003	
	C7	Holness, Mark, Up-regulation of pyruvate dehydrogenase... Biochemical Journal, V. 366, N. 3 9/2002 839-846	
	C8	Gordon, et. al., Am J Med (1977) 62. 707-714	
	C9	Oliver, Proc Nat Acad (2001) 98:5306-11	
	C10	Guerre-Millo, J Bio Chem (2000) 275: 16638-16642	
	C11	Sugden, Diabetes (2001) 50(12) 2729-36	
Examiner Signature			DATE CONSIDERED

<sup>7</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation or abstract is attached.